Enhancing vaccine effectiveness with delivery technology

Beitelshees, Marie; Li, Yang; Pfeifer, Blaine A.

doi:10.1016/j.copbio.2016.02.022

Cited by 10 publications

(12 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results thus far presented prompted a second evaluation, summarized in Figure 6 , using a protein, PncO, previously identified as an antigen for pneumococcal disease [ 8 , 12 , 15 , 19 ]. In particular, PncO was indicated as a biomarker associated with virulent S. pneumoniae cells, thus serving as a good antigen candidate in LEPS vaccine formulations [ 15 , 16 , 24 , 25 , 26 ]. Fixing the polysaccharide content of the LEPS formulation to that of serotype 3, encapsulation efficiency was compared across subsequent protein surface attachment using either GFP or PncO, with encapsulation retained at levels ≥61%.…”

Section: Resultsmentioning

confidence: 99%

“…In response, our research has focused on an alternative vaccine platform termed Liposomal Encapsulation of Polysaccharides (LEPS), in which a liposomal carrier simultaneously encapsulates polysaccharide content while allowing for the surface attachment of protein content ( Figure 1 ) [ 8 , 12 , 15 , 16 ]. The end result is a glycoconjugate mimic that offers a simpler, noncovalent form of polysaccharide–protein co-localization and a more tractable and scalable route to full serotype vaccine coverage.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System

et al. 2020

View full text Add to dashboard Cite

The Liposomal Encapsulation of Polysaccharides (LEPS) dual antigen vaccine carrier system was assessed across two distinct polysaccharides for encapsulation efficiency, subsequent liposomal surface adornment with protein, adjuvant addition, and size and charge metrics. The polysaccharides derive from two different serotypes of Streptococcus pneumoniae and have traditionally served as the active ingredients of vaccines against pneumococcal disease. The LEPS system was designed to mimic glycoconjugate vaccines that covalently couple polysaccharides to protein carriers; however, the LEPS system uses a noncovalent co-localization mechanism through protein liposomal surface attachment. In an effort to more thoroughly characterize the LEPS system across individual vaccine components and thus support broader future utility, polysaccharides from S. pneumoniae serotypes 3 and 4 were systematically compared within the LEPS framework both pre- and post-surface protein attachment. For both polysaccharides, ≥85% encapsulation efficiency was achieved prior to protein surface attachment. Upon protein attachment with either a model protein (GFP) or a pneumococcal disease antigen (PncO), polysaccharide encapsulation was maintained at ≥61% encapsulation efficiency. Final LEPS carriers were also evaluated with and without alum as an included adjuvant, with encapsulation efficiency maintained at ≥30%, while protein surface attachment efficiency was maintained at ≥~50%. Finally, similar trends and distributions were observed across the different polysaccharides when assessed for liposomal zeta potential and size.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Other considerations are choice of carrier, delivery vehicle [91] (including bacteria [92] or viral vectors [93] ), and administration route (intravenous, intratumoral, subcutaneous, intra-lymph node, nasal, ingested). Further afield, cancer vaccine engineering has emerged to offer benefits such as lymph node targeting, reduced systemic toxicity, elimination of ex vivo expansion requirements, and controlled release of immunomodulators while ignoring suppressive signals [94][95][96] .…”

Section: Vaccine Formulation and Administrationmentioning

confidence: 99%

A primer on recent developments in cancer immunotherapy, with a focus on neoantigen vaccines

Tokuyasu¹,

Huang²

2018

JCMT

View full text Add to dashboard Cite

Cancer immunotherapy has now been conclusively shown to be capable of producing durable responses for a substantial number of patients. Adoptive cell transfer and checkpoint blockade therapies in particular both demonstrate that antigen-specific immune responses can be dramatically effective, even in previously refractory late stage disease. Such developments, together with advances in technology, have strongly encouraged revisiting the concept of neoantigen vaccines. Here we introduce basic ideas in the field to allow investigators from diverse backgrounds to understand these developments, grasp current issues, and contribute to further progress.

show abstract

“…Ranging from aerosols and oral routes to microneedles, jet injectors, and micro/nanoparticles, the degree of sophistication and preclinical success of these myriad approaches have been quite remarkable [6]. Drug delivery approaches have attempted to improve vaccinations by changing the route of administration, by extending residence time on mucosal surfaces, promoting accumulation in secondary lymphoid tissue, or by modifying the rate of protein and/or adjuvant release.…”

Section: Overcoming Formulation Challenges For the Next Generation Ofmentioning

confidence: 99%

“…New techniques such as intravital microscopy and analytical equipment capable of simulating an injection site will help illuminate what is happening to vaccine components after administration. Improving the stability or maintaining association of antigen and adjuvant in vivo may be a real opportunity for drug delivery technologists [2,6,11].…”

Section: Expert Opinionmentioning

confidence: 99%